Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 17
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and over
Other
06-2247
NCT00442533
2.
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 120
Pharmaceutical / Industry
A6181111
NCT00428597
3.
Efficacy and Safety of Everolimus (RAD001) in Female or Male Patients 18 Years or Older With Advanced Neuroendocrine Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
CRAD001C2324
NCT00510068
Last Modified:
8/1/2008
 
First Published:
9/23/2005
4.
Phase I/II Pilot Study of Fluorouracil, Leucovorin Calcium, and Oxaliplatin (FOLFOX) With Bevacizumab in Patients With Advanced Neuroendocrine Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI
UCSF-04458
NCT00227617
5.
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
07-325
NCT00576680
6.
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
END0002
97273, END0002, NCT00398320, NCT00398320
Last Modified:
10/26/2007
 
First Published:
3/22/2007
7.
Phase II Study of Pazopanib Hydrochloride in Patients With Low- or Intermediate-Grade Advanced Neuroendocrine Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
21 and over
NCI
MDA-2006-0077
MDACC 2006-0077, 7650, NCT00454363
8.
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
MCC-14888
NCT00434109
9.
TheraSphere for the Treatment of Liver Metastases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
G040148
NCT00511862
10.
Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
PTK787/ZK222584
LSU IRB-6355, NCT00590343
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute